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To highlight the importance of the need for new treatment modalities, this study aimed to 
characterise the experience of patients with post-infectious olfactory dysfunction (PIOD) in terms of 
the treatment they received. 
Methods 
An online survey was hosted by the Norwich Clinical Trials Unit on the secure Redcap Server. 
Members of the charity Fifth Sense (the UK charity that represents and supports people affected by 
smell and taste disorders) were invited to participate. 
Results 
There were 149 respondents from which 127 had identified themselves as having (or had) PIOD. The 
age range of respondents to the survey was 28-85 with a mean of 58 12 years with the duration of 
their disorder less than 5 years in 63% of cases. Respondents reported experiencing variable treatment 
with oral and/or intranasal steroids given typically (28%), often with no benefit, but with 50% receiving 
no treatment whatsoever; only 3% reported undertaking olfactory training.  Over two thirds of 
patients experience parosmia and up to 5 years from the onset of the problem were still actively 
seeking a solution. 
Conclusion 
There appears to be a need to encourage greater use of guidelines for olfactory disorders amongst 
medical practitioners and also to develop more effective treatments for patients with PIOD, where 







Loss of smell is a common complaint in adults and yet has been underestimated. Anosmia, complete 
loss of smell, is thought to affect at least 1-5% of the population[1]. Based on European estimates [2], 
anosmia is more prevalent than profound hearing loss or blindness in the UK as data from the Royal 
National Institutes for the Blind and the Deaf respectively show that 2 million (3%) are affected by 
sight loss [3] and 900,000 (1.3%) are affected by profound hearing loss [4]. Causes for olfactory loss 
are varied but the main diagnostic groups include sinonasal disease (62%) and post-infectious 
olfactory dysfunction (PIOD) (11%)[5]. Olfactory dysfunction has now emerged as a key symptom in 
the coronavirus pandemic and it is possible we may see a cohort of patients with lasting problems 
following the peak of the Covid-19 impact[6-8]. Historically, there is wide variation in clinical practice 
reported by clinicians to patients on prognosis or treatment[9]. Guidelines for the overall 
management of olfactory disorders now exist in the Position Paper on Olfactory Dysfunction[1] and 
recently the Clinical Olfactory Working Group has produced a consensus statement on managing 
PIOD[10], but the impact of those guidelines have yet to penetrate routine clinical practice.  
Previously published data has shown the high impact on quality of life experienced by olfactory 
disorder patients, including depression, anxiety, impairment of eating experience, feelings of isolation 
and relationship difficulties[11, 12]. Most patients suffer a loss of flavour perception which can 
adversely affect their appetite[13], but this can be made even worse when parosmia is also present. 
Given the number of potential treatment options for PIOD that have been proposed but yet to 
undergo formal evaluation through a randomised clinical trial[14], there is a pressing need to deliver 
more RCTs in this area. A recent German study has highlighted topical Vitamin A as a potential 
therapeutic agent for further evaluation[15]. In anticipation of setting up a clinical trial to evaluate the 
role of vitamin A intranasally for PIOD we sought to generate evidence of need to funders through 
Public and Patient Involvement (PPI) in partnership with the charity Fifth Sense that represents 
patients affected by Smell & Taste disorders in the UK (www.fifthsense.org.uk).  
The aim of this study was to characterise the experience of patients with PIOD in terms of the 
treatment they received in order to demonstrate any unmet need. 
Materials and Methods 
A survey was set up by the Norwich Clinical Trials Unit in conjunction with Fifth Sense and was 
designed by the authors (clinician and 2 patients with olfactory dysfunction). This was the uploaded 
on to the REDCap server at the Norwich Clinical Trials Unit; REDCap is a secure web application for 
building and managing online surveys and databases. A secure link was then circulated to members 
of Fifth Sense via e-mail as part of the PPI in the proposed trial application. The questions were 
designed to be applicable to PIOD sufferers in the UK and beyond. The survey was live for 2 months 
at the beginning of 2019. As this study was considered service evaluation, no ethical approval was 
needed according to the UK Health Research Authority guidelines [16]. 
Eligibility criteria: 
The survey was sent out to members of Fifth Sense who had identified themselves on joining the 
charity as having suffered olfactory dysfunction following an upper respiratory tract infection; 
participants had to recall symptoms of olfactory dysfunction following on directly from an upper 
respiratory tract infection. Responses were screened to remove anyone not identifying with PIOD and 
also to document co-existing sinonasal disorders including chronic rhinosinusitis, allergic rhinitis and 
nasal septal deviation which would be considered exclusion criteria in any subsequent trial. 
Survey Questions: 
Only the questions that did not refer specifically to involvement in a clinical trial are listed here. 
1. Do you have a reduced sense of smell because of a bad cold/infection you suffered? If no, you can 
stop the survey here. 
2. Did you suffer the cold/infection … less than 5 years ago? more than 5 years ago? 
3. Have you suffered from smell distortions (parosmia) or smell hallucinations (phantosmia)? 
4. Have you received any treatment to date? 
5. What treatment did you receive? (free text) 
6. Do you have any of the following problems? 
• Chronic rhinosinusitis (CRS) with or without nasal polyps? 
• Allergic rhinitis (hayfever)? 
• Severe deviation of the nasal septum? 
• I am using nasal medications at the moment 
7. Do you have any comments about smell loss due to a bad cold? 
8. If you are willing, please tell us your age 
Analysis: 
Given the nature of the study, no formal statistical analysis was undertaken; rather a descriptive 
narrative of the survey findings is presented including representative comments left by some patients. 
Results 
There were 149 Fifth Sense members who responded to the survey; of these 127 declared they had 
experienced PIOD. In the 127 PIOD respondents, 13 reported both CRS and AR, 18 just AR and 13 just 
CRS. Seven reported a severe septal deviation. The age range was 28-85 with a mean of 57 11. The 
duration of their disorder was less than 5 years in 63% of cases, with 64% reporting the presence of 
parosmia. In terms of treatment received, 50% had not received any treatment at all from their GP or 
ENT specialist; 24 members reported they were currently using nasal medications. Prior medication 
use included oral and intra-nasal corticosteroids (OCS, INCS) as the most commonly given in 28% 
(n=36). Additionally, antibiotics were received by 5% of patients despite a lack of evidence to support 
this and only 3% of participants reported olfactory training as a treatment they had been advised to 
perform. Figure 1 shows the treatments reported by respondents (some respondents reported more 
than one treatment). Twenty-four patients (without other reported sinonasal disorders) (19%) also 
reported having undergone an MRI and/or CT scans. 
Quotations from survey participants 
Participants were asked to leave comments and many did. Here are a few examples: 
“I am very low with the effects of PIOD has had on my life; it affects my partner too :-(.” 
“I lost my very sensitive sense of smell suddenly after a really bad infection. I went to my GP a few 
months later but he said bad luck.  He did not refer me to an ENT specialist, so I do not know if I have 
any of the medical conditions mentioned. The only thing I can smell consistently is orange peel. Very 
occasionally I get a brief 'glimpse' of another smell e.g. fish or carnations.”    
“It was a severe cold when I lost my voice completely twice. I was shocked that my smell went and 
keep hoping it will come back. Even though I saw an ENT consultant and tried steroids no change.” 
“It was a prolonged dose of bad cold then flu in the run up to Christmas 2017 that finally wiped mine 
out. I could taste something when I started eating my Christmas dinner but by the end of the meal I 
couldn't taste or smell anything. Since then its improved a little but only a little and something has 
really left my life. It’s taken the colour from day to day life.” 
“I have only ever had the flu twice in my life, with the last bout in January 2018 resulting in the complete 
loss of my sense of taste and smell.  I still remember the point at which the loss occurred.  It was a 
serious flu, around the time the Ozzy Flu epidemic was rife in the area I live.  The virus left me bed 
ridden for a few days and it was around the 4/5 day where the virus was at its worst that I remember 
a complete blockage occurring where I struggled for breath, and after this point I have been unable to 
taste or smell anything.” 
“Lost smell and taste 7 months ago following flu, have had a very negative response from the medical 
profession including 1 doctor who was extremely rude to me.” 
Discussion 
The survey helps to delineate the paucity of effective treatment provision for this particular group of 
patients with olfactory dysfunction. It is particularly notable that only 3% of survey participants 
reported undertaking olfactory training as a treatment option, which given the increasing volume of 
evidence to support this option[17], is surprising. This may well be a product the current knowledge 
of their physicians who treated them Furthermore, it is interesting that some patients underwent 
imaging which would not ordinarily indicated if the history is clear and endoscopy shows no evidence 
of intranasal pathology[1]; this suggests that work is needed to disseminate the guidelines from the 
2017 Position Paper on Olfactory Dysfunction. Although PIOD represents a smaller percentage of the 
causes of olfactory disorders overall compared to chronic rhinosinusitis[5], the latter condition 
benefits from greater attention and PIOD patients typically make up a higher percentage of attendees 
in a specialist clinic (typically about 25%)[18]. Managing smell loss has previously been identified as a 
source of frustration for clinicians in Otorhinolaryngology, in part due to the lack of therapeutic 
options to deploy[9] but can often lead to dismissal of patients[19, 12]. A number of medical and 
complimentary medicine options have been studied in case series but precious few have been 
subjected to the scientific rigour of a randomised controlled trial[14]. The recent position paper on 
olfactory dysfunction has outlined the utility of smell training[1] but despite increasing uptake of this 
option through information provided on the Fifth Sense website, significant numbers of patients 
remain markedly affected. It is perhaps the apparent dearth of therapeutic agents that are deemed 
effective by clinicians that leads to the picture we see here of half the patients reporting a lack of 
treatment; certainly 93% of participants expressed a strong willingness to participate in any future 
trials. Other studies have charted the experience of those with olfactory disorders [20-22] but 
guidelines have only more recently developed that help to guide clinicians on generic management 
and specific treatment recommendations [1, 10, 23] and therefore medical practitioners are perhaps 
likely to remain unfamiliar with the best approach to management.  
This survey has its limitations. Firstly, it may be biased in its respondents being those who have a 
persistent olfactory disturbance; however, these are the patients who present to doctors seeking 
further help and for whom any first line treatment has failed. Secondly the participants have self-
reported their PIOD and any sinonasal disorders, however our previous work has shown that self-
reporting from Fifth Sense members tends to reflect the proportions of doctor-diagnosed cases seen 
in a specialist smell and taste clinic [24], so we do believe the respondents here are likely to reasonably 
accurately reflect a genuine group of PIOD patients. We didn’t however capture any information on 
who their prior medical contact was with such as GP, otorhinolaryngologist or specialist olfactologist. 
Post-viral olfactory loss typically occurs following viral injury to the olfactory epithelium that leaves 
the olfactory sensory neurones lacking in cilia and effectively non-functional[25], although the current 
coronavirus, Covid-19 may wreak its havoc on the olfactory system by different mechanisms[8]. 
Treatment of this condition does require some insight into the pathophysiology in order to target 
potential pathways where therapeutic agents can act. It may be possible that stem cell therapy yields 
some hope in this area in the future.  Presently, topical treatments including theophylline[26], Vitamin 
A [15] and sodium citrate[27-29] have shown some promise and should be considered among 
potential candidates for more rigorous scientific evaluation.  
Conclusion  
We hope that this survey’s findings will provide a platform for more research, including clinical trials, 
to be conducted in the area of PIOD by demonstrating evidence of a need in those persistently 
affected.  We also hope that that it serves as a reminder to clinicians encountering these patients to 
consider updating their knowledge of managing olfactory disorders, both in PIOD and other causes of 
olfactory dysfunction, especially in light of current guidelines such as those produced by the Clinical 
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Figure 1: Prior medication use by respondents (number of respondents for each medication) – some 




OCS = oral corticosteroids 
INCS = intranasal corticosteroids 
ND = nasal douching 
Abx = antibiotics 
 
